Literature DB >> 9720981

Plasma dehydroepiandrosterone sulfate in unipolar major depression. Short communication.

M Takebayashi1, A Kagaya, Y Uchitomi, A Kugaya, M Muraoka, N Yokota, J Horiguchi, S Yamawaki.   

Abstract

We investigated plasma dehydroepiandrosterone sulfate (DHEAS) and cortisol levels in 12 patients with unipolar depression and 11 matched normal controls. The depressed patients showed significantly higher values of plasma DHEAS and cortisol than the controls. After 4 weeks of treatment with antidepressants (mainly clomiplamine), the high plasma DHEAS levels recovered. This finding showed the possible relationship between plasma DHEAS levels and depression, as well as cortisol levels.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9720981     DOI： 10.1007/s007020050077

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  11 in total

Review 1.  Endocrine disturbances in depression.

Authors:  M A Tichomirowa; M E Keck; H J Schneider; M Paez-Pereda; U Renner; F Holsboer; G K Stalla
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

Review 2.  Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Shang-Yi Tsai; Tomohisa Mori; Michiko Fujimoto; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2011-03-05       Impact factor: 6.902

Review 3.  Neurosteroid, GABAergic and hypothalamic pituitary adrenal (HPA) axis regulation: what is the current state of knowledge in humans?

Authors:  Shannon K Crowley; Susan S Girdler
Journal:  Psychopharmacology (Berl)       Date:  2014-04-23       Impact factor: 4.530

4.  Concurrent and prospective associations between HPA axis activity and depression symptoms in newlywed women.

Authors:  Fiona Ge; Paula R Pietromonaco; Casey J DeBuse; Sally I Powers; Douglas A Granger
Journal:  Psychoneuroendocrinology       Date:  2016-07-22       Impact factor: 4.905

5.  Genetic and environmental effects on diurnal dehydroepiandrosterone sulfate concentrations in middle-aged men.

Authors:  Elizabeth C Prom-Wormley; Timothy P York; Kristen C Jacobson; Lindon J Eaves; Sally P Mendoza; Dirk Hellhammer; Nicole Maninger; Seymour Levine; Sonia Lupien; Michael J Lyons; Richard Hauger; Hong Xian; Carol E Franz; William S Kremen
Journal:  Psychoneuroendocrinology       Date:  2011-05-12       Impact factor: 4.905

6.  Higher serum DHEA concentrations before and after SSRI treatment are associated with remission of major depression.

Authors:  Christina M Hough; Daniel Lindqvist; Elissa S Epel; Molly St Denis; Victor I Reus; F Saverio Bersani; Rebecca Rosser; Laura Mahan; Heather M Burke; Owen M Wolkowitz; Synthia H Mellon
Journal:  Psychoneuroendocrinology       Date:  2016-12-05       Impact factor: 4.905

7.  Higher DHEA-S (dehydroepiandrosterone sulfate) levels are associated with depressive symptoms during the menopausal transition: results from the PENN Ovarian Aging Study.

Authors:  Mary Frances Morrison; Ellen W Freeman; Hui Lin; Mary D Sammel
Journal:  Arch Womens Ment Health       Date:  2011-07-20       Impact factor: 3.633

Review 8.  The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.

Authors:  Erin M MacKenzie; John Odontiadis; Jean-Michel Le Mellédo; Trevor I Prior; Glen B I Baker
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

Review 9.  Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS).

Authors:  Nicole Maninger; Owen M Wolkowitz; Victor I Reus; Elissa S Epel; Synthia H Mellon
Journal:  Front Neuroendocrinol       Date:  2008-12-03       Impact factor: 8.606

10.  Neuroactive steroids after estrogen exposure in depressed postmenopausal women treated with sertraline and asymptomatic postmenopausal women.

Authors:  Melinda L Morgan; Andrea J Rapkin; Giovanni Biggio; Mariangela Serra; Maria Giuseppina Pisu; Natalie Rasgon
Journal:  Arch Womens Ment Health       Date:  2009-09-03       Impact factor: 3.633
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.